Search research articles
Contact Us
Filters
Showing results (131-140 of 227) with videos related to
Page
of 23
Sort By:
European Urology
|
December 3, 2015
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M Tannir, Eric Jonasch, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M Regan, Lillian Werner, Sumati Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Elaine Chang, Jiaxi Zhou, Chi Song, et al.
Cancer Immunology, Immunotherapy : CII
|
October 4, 2016
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2
Wei Wang, Amy K Erbe, Mikayla Gallenberger, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 14, 2016
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Andre P Fay, Guillermo de Velasco, Thai H Ho, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Page
of 23
Search research articles
Search
Showing results (131-140 of 227) with videos related to
Sort By:
Page
of 23
European Urology
|
December 3, 2015
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M Tannir, Eric Jonasch, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M Regan, Lillian Werner, Sumati Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Elaine Chang, Jiaxi Zhou, Chi Song, et al.
Cancer Immunology, Immunotherapy : CII
|
October 4, 2016
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2
Wei Wang, Amy K Erbe, Mikayla Gallenberger, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 14, 2016
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Andre P Fay, Guillermo de Velasco, Thai H Ho, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Page
of 23